James E. Barrett

TL;DR: Linking molecular profiles with drug sensitivity patterns identifies novel biomarkers, including a signature outperforming RAS/RAF mutations in predicting sensitivity to the EGFR inhibitor cetuximab.

TL;DR: Application of eFORGE to 20 publicly available EWAS datasets identified disease-relevant cell types for several common diseases, a stem cell-like signature in cancer, and demonstrated the ability to detect cell-composition effects for EWAS performed on heterogeneous tissues.

TL;DR: It is suggested that silent cerebral infarcts in sickle cell anemia may be associated with higher systolic blood pressure, lower HbF levels, hypercoagulability, inflammation and atherosclerotic lipoproteins.

TL;DR: Wang et al. as discussed by the authors developed the DNA methylation-based women's risk IDentification for Breast Cancer index (WID-BC-index) that identifies women with breast cancer with an AUROC (Area Under the Receiver Operator Characteristic) of 0.84 (95% CI: 0.80-0.88) and 0.81 (95 % CI:0.76 −0.86) in internal and external validation sets, respectively.

TL;DR: This proposed model belongs to the class of accelerated failure time models where it focuses on directly characterising the relationship between covariates and event times without any explicit assumptions on what form the hazard rates take.